Magic Mushrooms and Ecstasy: New Treatment For Autism Spectrum Disorders?
Written by Natan Ponieman,
Much like cannabis, psychedelics are catching the eye of investors for their potential to break out of their classification of scheduled substances and move closer to becoming valuable tools in the treatment of mental health issues.
Researchers and public companies are currently gathering substantial evidence in phase 2 and phase 3 clinical trials for the therapeutic potential of psychedelic molecules in indications like PTSD, depression and substance addiction.
For now, autism spectrum disorders have, for the most part, remained outside the realm of psychedelic medicine. However, as research into psychedelics advances, some companies in the space are aiming to create psychedelics-based solutions targeting ailments in this category.
Psilocybin For Autism and Fragile X Syndrome
Autism spectrum disorders can have severe consequences in the lives of patients and their families. With a prevalence of approximately 1 in 54 children in the U.S., the estimated cost of autism for the average family reaches $60,000 a year through the patient’s childhood.
Disorders in this spectrum are some of the most common indications lacking a known cure or overall satisfactory solution. According to the nonprofit Autism Speaks, the economic cost of caring for Americans with autism reached $268 billion in 2015 and would rise to $461 billion by 2025 in the absence of more effective interventions and support across the patient’s life span.